24 completed, 13 terminated, 5 active not recruiting, 5 recruiting. 29 Phase 1, 26 Phase 2, 5 Phase 3, 1 Not applicable.
Follow MacroGenics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency Lorigerlimab - Pancreatic Adenocarcinoma, Homologous Recombination Deficiency | Phase 2 | Not yet recruiting | University of Miami | 40 | 2027-01-01 | 2026-10-13 |
| A Study of MGC030 in Participants With Advanced Solid Tumors MGC030 - Urothelial Cancer, GastroEsophageal Cancer | Phase 1 | Not yet recruiting | MacroGenics | 314 | 2026-09-01 | 2026-09-16 |
| Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] Regorafenib (CT), Lorigerlimab - Colorectal Cancer, Regorafenib | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 16 | 2026-02-11 | 2026-08-27 |
| A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer Regorafenib, Lorigerlimab - Rectal Cancer, Rectal Cancer Recurrent | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-10-27 | 2026-02-25 | |
| A Study of Lorigerlimab in Participants With Advanced Solid Tumors Lorigerlimab - Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | Recruiting | MacroGenics | 80 | 2025-05-01 | 2026-06-02 |
| A Study of MGC028 in Participants With Advanced Solid Tumors MGC028 - Advanced Solid Tumors, NSCLC Adenocarcinoma | Phase 1 | Recruiting | MacroGenics | 124 | 2025-02-13 | 2026-04-27 |
| MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer MGC018 - Extensive-stage Small-cell Lung Cancer | Phase 2 | Active not recruiting | Georgetown University | 9 | 2024-04-15 | 2026-06-25 |
| A Study of MGC026 in Participants With Advanced Solid Tumors MGC026 Dose Escalation, MGC026 Dose for Expansion - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Recruiting | MacroGenics | 250 | 2024-03-06 | 2026-08-11 |
| Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer Enoblituzumab, Standard of Care - Prostate Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 219 | 2024-02-16 | 2026-07-24 |
| A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer lorigerlimab, docetaxel, Prednisone - Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms | Phase 2 | Completed | MacroGenics | 154 | 2023-09-28 | 2026-05-22 |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
| Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) Lorigerlimab - Metastatic Cancer, Cervical Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 60 | 2022-12-13 | 2026-09-17 |
| Post-transplant Flotetuzumab for AML Flotetuzumab - Leukemia, Myeloid, Acute | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 3 | 2022-10-20 | 2025-09-12 |
| A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy MGD020, MGD014 - Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human | Phase 1 | Completed | MacroGenics | 17 | 2022-09-26 | 2025-03-28 |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies MGD024 - Leukemia, Acute Myeloid, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | MacroGenics | 130 | 2022-07-13 | 2026-07-28 |
| Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer Margetuximab, Tucatinib, Capecitabine - Metastatic Breast Cancer, Advanced Breast Cancer | Phase 2 | Withdrawn | MedSIR | 2022-05-15 | 2022-07-11 | |
| A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors vobramitamab duocarmazine, lorigerlimab - Advanced Solid Tumor, Castration-Resistant Prostatic Cancer | Phase 1 | Completed | MacroGenics | 31 | 2022-04-19 | 2025-10-14 |
| Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Flotetuzumab, Donor lymphocyte infusion - Relapsed Acute Myeloid Leukemia | Phase 2 | Terminated | Washington University School of Medicine | 11 | 2021-05-20 | 2024-12-06 |
| Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer Enoblituzumab, Retifanlimab, Tebotelimab - Head and Neck Cancer, Head and Neck Neoplasms | Phase 2 | Terminated | MacroGenics | 62 | 2021-03-17 | 2023-12-20 |
| First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors IMGC936 - Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | ImmunoGen, Inc. | 56 | 2020-10-29 | 2025-01-15 |
Showing 20 of 54. Sign in to see all of them.
Melanoma (10) · Carcinoma, Non-Small-Cell Lung (9) · Breast Neoplasms (7) · Squamous Cell Carcinoma of Head and Neck (7) · Colorectal Neoplasms (6) · Pancreatic Neoplasms (6) · Stomach Neoplasms (6) · Carcinoma, Renal Cell (5) · Prostatic Neoplasms (5) · Diabetes Mellitus, Type 1 (4) · Head and Neck Neoplasms (4) · Leukemia, Myeloid, Acute (4) · Prostatic Neoplasms, Castration-Resistant (4) · Small Cell Lung Carcinoma (4) · Urinary Bladder Neoplasms (4)
margetuximab (8) · teplizumab (4) · Trastuzumab (3) · pembrolizumab (2) · regorafenib (2) · Blood Specimen Collection (1) · Capecitabine (1) · Docetaxel (1) · Drug Therapy (1) · Gemcitabine (1) · Hepatitis A Vaccines (1) · Ipilimumab (1) · Ogivri (1) · Paclitaxel (1) · Prednisone (1)
United States (46) · Spain (11) · Poland (10) · United Kingdom (8) · Australia (7) · Italy (6) · South Korea (6) · Canada (5) · France (5) · Germany (5) · Ukraine (5) · Belgium (4) · Bulgaria (4) · Israel (4) · Netherlands (4)
Ashley Ward, MD (3) · Ashley L. Ward, MD (2) · Denise Casey, MD (2) · Frank Perabo, MD, PhD (2) · Pepi Pencheva, M.D. (2) · Adrienne Waks, MD (1) · Alisha H Bent, MD (1) · Amir Jazeri, MD (1) · Ashley Ward, M.D. (1) · Chul Kim, MD (1) · Denise Casey, M.D. (1) · Eugene Shenderov (1) · Eugene Shenderov, MD, PhD (1)
PMID 20179219, PMID 21719095, PMID 28119295, PMID 32653053, PMID 32929488, PMID 33263418, PMID 33480963, PMID 35414591, PMID 35511740, PMID 36332179, PMID 37012549, PMID 37104758, PMID 37857711, PMID 38182653, PMID 39735417, PMID 41166694, PMID 41811823
272201500032C-2-0-1 (1), 272201500032C-P00008-9999-1 (1), P01CA015396 (1), P50CA171963 (1)